Abstract
This study reports our experience in metabolic radiotherapy in 54 children with advanced neuroblastoma treated between 1986 and 1992 with 131-I-metaiodobenzylguanidine (131-I MIBG). One child was treated at diagnosis, 8 for a primary tumor inoperable after chemotherapy, 20 children had been resistant to first line therapy, 4 had suffered a local relapse, 4 a disseminated relapse and 17 had suffered a disseminated relapse without overt bone infiltration. One child was treated initially because of resistance to first-line therapy, and subsequently for a local relapse. A total of 125 courses of 131-I MIBG was administered, with doses ranging from 2.6 to 6.0 GBq (median 3.7 GBq). One child received five courses, 3 four courses, 21 three courses, 13 two courses and 16 one course of 131-I MIBG. The most common toxic effect was thrombocytopenia. Seven children presented a reduced thyroideal function and 5 are presently receiving thyroxine. There were 9 major responses (two complete), and 7 minor responses. Responses were seen more commonly in children whose only lesion was a residual primary tumor and in children who had not been pretreated by chemotherapy where experienced disseminated relapse.
| Original language | Italian |
|---|---|
| Pages (from-to) | 502-506 |
| Number of pages | 5 |
| Journal | Rivista Italiana di Pediatria |
| Volume | 19 |
| Issue number | 5 |
| Publication status | Published - 1993 |
Fingerprint
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
Cite this
TRATTAMENTO CON 131-I METAIODOBENZILGUANIDINA IN BAMBINI AFFETTI DA NEUROBLASTOMA. / Garaventa, A.; Claudiani, F.; Pianca, C.; Picco, P.; Nigro, M.; Conte, M.; Bertolazzi, L.; Pizzoccaro, C.; Scopinaro, G.; De Bernardi, B.
In: Rivista Italiana di Pediatria, Vol. 19, No. 5, 1993, p. 502-506.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - TRATTAMENTO CON 131-I METAIODOBENZILGUANIDINA IN BAMBINI AFFETTI DA NEUROBLASTOMA
AU - Garaventa, A.
AU - Claudiani, F.
AU - Pianca, C.
AU - Picco, P.
AU - Nigro, M.
AU - Conte, M.
AU - Bertolazzi, L.
AU - Pizzoccaro, C.
AU - Scopinaro, G.
AU - De Bernardi, B.
PY - 1993
Y1 - 1993
N2 - This study reports our experience in metabolic radiotherapy in 54 children with advanced neuroblastoma treated between 1986 and 1992 with 131-I-metaiodobenzylguanidine (131-I MIBG). One child was treated at diagnosis, 8 for a primary tumor inoperable after chemotherapy, 20 children had been resistant to first line therapy, 4 had suffered a local relapse, 4 a disseminated relapse and 17 had suffered a disseminated relapse without overt bone infiltration. One child was treated initially because of resistance to first-line therapy, and subsequently for a local relapse. A total of 125 courses of 131-I MIBG was administered, with doses ranging from 2.6 to 6.0 GBq (median 3.7 GBq). One child received five courses, 3 four courses, 21 three courses, 13 two courses and 16 one course of 131-I MIBG. The most common toxic effect was thrombocytopenia. Seven children presented a reduced thyroideal function and 5 are presently receiving thyroxine. There were 9 major responses (two complete), and 7 minor responses. Responses were seen more commonly in children whose only lesion was a residual primary tumor and in children who had not been pretreated by chemotherapy where experienced disseminated relapse.
AB - This study reports our experience in metabolic radiotherapy in 54 children with advanced neuroblastoma treated between 1986 and 1992 with 131-I-metaiodobenzylguanidine (131-I MIBG). One child was treated at diagnosis, 8 for a primary tumor inoperable after chemotherapy, 20 children had been resistant to first line therapy, 4 had suffered a local relapse, 4 a disseminated relapse and 17 had suffered a disseminated relapse without overt bone infiltration. One child was treated initially because of resistance to first-line therapy, and subsequently for a local relapse. A total of 125 courses of 131-I MIBG was administered, with doses ranging from 2.6 to 6.0 GBq (median 3.7 GBq). One child received five courses, 3 four courses, 21 three courses, 13 two courses and 16 one course of 131-I MIBG. The most common toxic effect was thrombocytopenia. Seven children presented a reduced thyroideal function and 5 are presently receiving thyroxine. There were 9 major responses (two complete), and 7 minor responses. Responses were seen more commonly in children whose only lesion was a residual primary tumor and in children who had not been pretreated by chemotherapy where experienced disseminated relapse.
KW - I-131 meta iodobenzylguanidine
KW - neuroblastoma
KW - therapy
UR - http://www.scopus.com/inward/record.url?scp=0027820488&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027820488&partnerID=8YFLogxK
M3 - Articolo
AN - SCOPUS:0027820488
VL - 19
SP - 502
EP - 506
JO - Rivista Italiana di Pediatria
JF - Rivista Italiana di Pediatria
SN - 0392-5161
IS - 5
ER -